In this episode of “Blood Cancer Talks,” Luciano Costa MD, PhD, of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, joins the show to provide listeners with an overview of measurable residual disease (MRD) in multiple myeloma (MM).
Dr. Costa speaks about the use of MRD as a prognostic biomarker, as well as how it can be used as a tool to adapt therapy, and its use as a surrogate clinical trial endpoint. He also discusses the MASTER trial, which was the first to test an MRD-adapted treatment strategy in MM.
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer